Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Strong human endogenous retrovirus-specific T cell responses are associated with control of HIV-1 in chronic infection.

SenGupta D, Tandon R, Vieira RG, Ndhlovu LC, Lown-Hecht R, Ormsby CE, Loh L, Jones RB, Garrison KE, Martin JN, York VA, Spotts G, Reyes-Terán G, Ostrowski MA, Hecht FM, Deeks SG, Nixon DF.

J Virol. 2011 Jul;85(14):6977-85. doi: 10.1128/JVI.00179-11. Epub 2011 Apr 27.

2.

T cell responses to human endogenous retroviruses in HIV-1 infection.

Garrison KE, Jones RB, Meiklejohn DA, Anwar N, Ndhlovu LC, Chapman JM, Erickson AL, Agrawal A, Spotts G, Hecht FM, Rakoff-Nahoum S, Lenz J, Ostrowski MA, Nixon DF.

PLoS Pathog. 2007 Nov;3(11):e165.

3.

HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates.

Jones RB, Garrison KE, Mujib S, Mihajlovic V, Aidarus N, Hunter DV, Martin E, John VM, Zhan W, Faruk NF, Gyenes G, Sheppard NC, Priumboom-Brees IM, Goodwin DA, Chen L, Rieger M, Muscat-King S, Loudon PT, Stanley C, Holditch SJ, Wong JC, Clayton K, Duan E, Song H, Xu Y, SenGupta D, Tandon R, Sacha JB, Brockman MA, Benko E, Kovacs C, Nixon DF, Ostrowski MA.

J Clin Invest. 2012 Dec;122(12):4473-89. doi: 10.1172/JCI64560. Epub 2012 Nov 12.

4.

Human endogenous retrovirus expression is inversely associated with chronic immune activation in HIV-1 infection.

Ormsby CE, Sengupta D, Tandon R, Deeks SG, Martin JN, Jones RB, Ostrowski MA, Garrison KE, Vázquez-Pérez JA, Reyes-Terán G, Nixon DF.

PLoS One. 2012;7(8):e41021. doi: 10.1371/journal.pone.0041021. Epub 2012 Aug 7.

5.

Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection.

Zheng NN, McElrath MJ, Sow PS, Hawes SE, Diallo-Agne H, Stern JE, Li F, Mesher AL, Robinson AD, Gottlieb GS, Huang Y, Kiviat NB.

J Virol. 2007 Sep;81(17):9061-71. Epub 2007 Jun 20.

6.

New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.

Gahery H, Daniel N, Charmeteau B, Ourth L, Jackson A, Andrieu M, Choppin J, Salmon D, Pialoux G, Guillet JG.

AIDS Res Hum Retroviruses. 2006 Jul;22(7):684-94.

PMID:
16831093
7.

Human endogenous retrovirus K(HML-2) Gag- and Env-specific T-cell responses are infrequently detected in HIV-1-infected subjects using standard peptide matrix-based screening.

Jones RB, John VM, Hunter DV, Martin E, Mujib S, Mihajlovic V, Burgers PC, Luider TM, Gyenes G, Sheppard NC, Sengupta D, Tandon R, Yue FY, Benko E, Kovacs C, Nixon DF, Ostrowski MA.

Clin Vaccine Immunol. 2012 Feb;19(2):288-92. doi: 10.1128/CVI.05583-11. Epub 2011 Dec 28.

8.

Identification of human endogenous retrovirus-specific T cell responses in vertically HIV-1-infected subjects.

Tandon R, SenGupta D, Ndhlovu LC, Vieira RG, Jones RB, York VA, Vieira VA, Sharp ER, Wiznia AA, Ostrowski MA, Rosenberg MG, Nixon DF.

J Virol. 2011 Nov;85(21):11526-31. doi: 10.1128/JVI.05418-11. Epub 2011 Aug 31.

9.

Dominant ex vivo cross-stimulation of CD8+ T-cells with whole soluble gag protein in HIV-infected subjects.

Tavernier A, Jennes W, Fransen K, De Roo A, Kestens L.

J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):548-56.

PMID:
16652028
11.

Anti-HERV-K (HML-2) capsid antibody responses in HIV elite controllers.

de Mulder M, SenGupta D, Deeks SG, Martin JN, Pilcher CD, Hecht FM, Sacha JB, Nixon DF, Michaud HA.

Retrovirology. 2017 Aug 22;14(1):41. doi: 10.1186/s12977-017-0365-2.

12.

Characterization of HIV-1 Gag-specific T cell responses in chronically infected Indian population.

Kaushik S, Vajpayee M, Wig N, Seth P.

Clin Exp Immunol. 2005 Nov;142(2):388-97.

13.

Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1 infection.

Feeney ME, Draenert R, Roosevelt KA, Pelton SI, McIntosh K, Burchett SK, Mao C, Walker BD, Goulder PJ.

J Immunol. 2003 Dec 15;171(12):6968-75.

14.

Human endogenous retrovirus K(HML-2) Gag and Env specific T-cell responses are not detected in HTLV-I-infected subjects using standard peptide screening methods.

Jones RB, Leal FE, Hasenkrug AM, Segurado AC, Nixon DF, Ostrowski MA, Kallas EG.

J Negat Results Biomed. 2013 Jan 10;12:3. doi: 10.1186/1477-5751-12-3.

15.

Immunodominant HIV-1 Cd4+ T cell epitopes in chronic untreated clade C HIV-1 infection.

Ramduth D, Day CL, Thobakgale CF, Mkhwanazi NP, de Pierres C, Reddy S, van der Stok M, Mncube Z, Nair K, Moodley ES, Kaufmann DE, Streeck H, Coovadia HM, Kiepiela P, Goulder PJ, Walker BD.

PLoS One. 2009;4(4):e5013. doi: 10.1371/journal.pone.0005013. Epub 2009 Apr 7.

16.

Higher homologous and lower cross-reactive Gag-specific T-cell responses in human immunodeficiency virus type 2 (HIV-2) than in HIV-1 infection.

Jennes W, Camara M, Dièye T, Mboup S, Kestens L.

J Virol. 2008 Sep;82(17):8619-28. doi: 10.1128/JVI.00027-08. Epub 2008 Jun 18.

17.

Polyfunctional CD4(+) T cell responses in HIV-1-infected viral controllers compared with those in healthy recipients of an adjuvanted polyprotein HIV-1 vaccine.

Van Braeckel E, Desombere I, Clement F, Vandekerckhove L, Verhofstede C, Vogelaers D, Leroux-Roels G.

Vaccine. 2013 Aug 12;31(36):3739-46. doi: 10.1016/j.vaccine.2013.05.021. Epub 2013 May 21.

18.
19.

Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication.

Alatrakchi N, Duvivier C, Costagliola D, Samri A, Marcelin AG, Kamkamidze G, Astriti M, Agher R, Calvez V, Autran B, Katlama C.

AIDS. 2005 Jan 3;19(1):25-33.

PMID:
15627030
20.

Supplemental Content

Support Center